Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  214 results for ""RITUXIMAB""

Your Filters

Geographic : united kingdom Filter by : Subject
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.

Subjects: Lung Diseases, Interstitial*/Lung Diseases, Interstitial*/Lung Diseases, Interstitial*/drug therapy ; Lung Diseases, Interstitial*/Lung Diseases, Interstitial*/Lung Diseases, Interstitial*/etiology ; Connective Tissue Diseases*/Connective Tissue Diseases*/Connective Tissue Diseases*/complications

  • Source: The Lancet. Respiratory medicine [Lancet Respir Med] 2023 Jan; Vol. 11 (1), pp. 45-54. Date of Electronic Publication: 2022 Nov 11.Publisher: Elsevier Country of Publication: England NLM ID: 101605555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2619

Record details

Read More Add to Saved list
×
Academic Journal

Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy.

  • Authors : Doyle AJ; University College London Hospitals NHS Foundation Trust, London, United Kingdom.; Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom.

Subjects: Purpura, Thrombotic Thrombocytopenic*/Purpura, Thrombotic Thrombocytopenic*/Purpura, Thrombotic Thrombocytopenic*/therapy; Humans ; Rituximab/Rituximab/Rituximab/therapeutic use

  • Source: Blood [Blood] 2023 Jan 19; Vol. 141 (3), pp. 285-294.Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020

Record details

Read More Add to Saved list
×
Report

Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus.

Subjects: Antibodies, Monoclonal, Murine-Derived/Antibodies, Monoclonal, Murine-Derived/Antibodies, Monoclonal, Murine-Derived/*administration & dosage ; Autoantibodies/Autoantibodies/Autoantibodies/*drug effects ; Lupus Erythematosus, Systemic/Lupus Erythematosus, Systemic/Lupus Erythematosus, Systemic/*drug therapy

  • Source: Annals of the rheumatic diseases [Ann Rheum Dis] 2019 Aug; Vol. 78 (8), pp. 1140-1142. Date of Electronic Publication: 2019 Mar 28.Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2060

Record details

Read More Add to Saved list
×
Report

Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.

  • Authors : Eyre TA; Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK.; Fox CP

Subjects: Purines*/Purines*/Purines*/administration & dosage ; Purines*/Purines*/Purines*/adverse effects ; Quinazolinones*/Quinazolinones*/Quinazolinones*/administration & dosage

  • Source: British journal of haematology [Br J Haematol] 2019 Feb; Vol. 184 (4), pp. 667-671. Date of Electronic Publication: 2018 Feb 22.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2).

  • Authors : Lennox B; Department of Psychiatry, University of Oxford and Oxford Health NHS Foundation Trust, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, UK.; Yeeles K

Subjects: Antipsychotic Agents/Antipsychotic Agents/Antipsychotic Agents/*administration & dosage ; Immunoglobulins, Intravenous/Immunoglobulins, Intravenous/Immunoglobulins, Intravenous/*administration & dosage ; Psychotic Disorders/Psychotic Disorders/Psychotic Disorders/*drug therapy

  • Source: Trials [Trials] 2019 Jun 07; Vol. 20 (1), pp. 331. Date of Electronic Publication: 2019 Jun 07.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215

Record details

Read More Add to Saved list
×
Academic Journal

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.

  • Authors : Collett L; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.; Howard DR

Subjects: Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/*administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Leukemia, Lymphocytic, Chronic, B-Cell/Leukemia, Lymphocytic, Chronic, B-Cell/Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy

  • Source: Trials [Trials] 2017 Aug 22; Vol. 18 (1), pp. 387. Date of Electronic Publication: 2017 Aug 22.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215

Record details

Read More Add to Saved list
×
Academic Journal

Incidence and outcomes of post-transplant lymphoproliferative disease after 5365 solid-organ transplants over a 20-year period at two UK transplant centres.

  • Authors : Santarsieri A; Department of Haematology, Addenbrooke's Hospital, Cambridge, UK.; Anglia Ruskin University, Cambridge, UK.

Subjects: Epstein-Barr Virus Infections*/Epstein-Barr Virus Infections*/Epstein-Barr Virus Infections*/complications ; Lymphoproliferative Disorders*/Lymphoproliferative Disorders*/Lymphoproliferative Disorders*/drug therapy ; Lymphoproliferative Disorders*/Lymphoproliferative Disorders*/Lymphoproliferative Disorders*/epidemiology

  • Source: British journal of haematology [Br J Haematol] 2022 May; Vol. 197 (3), pp. 310-319. Date of Electronic Publication: 2022 Mar 02.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.

  • Authors : Berger JR; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, 3400 Convention Avenue, Room 765, Philadelphia, PA, 19104, USA. .; Malik V

Subjects: Arthritis, Rheumatoid/Arthritis, Rheumatoid/Arthritis, Rheumatoid/*drug therapy ; Granulomatosis with Polyangiitis/Granulomatosis with Polyangiitis/Granulomatosis with Polyangiitis/*drug therapy ; Immunologic Factors/Immunologic Factors/Immunologic Factors/*adverse effects

  • Source: Journal of neurovirology [J Neurovirol] 2018 Jun; Vol. 24 (3), pp. 323-331. Date of Electronic Publication: 2018 Mar 05.Publisher: Springer Country of Publication: United States NLM ID: 9508123 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register.

Subjects: Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*administration & dosage ; Biological Products/Biological Products/Biological Products/*administration & dosage ; Lupus Erythematosus, Systemic/Lupus Erythematosus, Systemic/Lupus Erythematosus, Systemic/*drug therapy

  • Source: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2018 Mar 01; Vol. 57 (3), pp. 470-479.Publisher: Oxford University Press Country of Publication: England NLM ID: 100883501 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.

  • Authors : Papakrivopoulou E; University College London Centre for Nephrology, Royal Free Campus, University College London, London, UK. .; University College London Institute of Child Health, University College London, London, UK. .

Subjects: Calcineurin Inhibitors*/Calcineurin Inhibitors*/Calcineurin Inhibitors*/administration & dosage ; Calcineurin Inhibitors*/Calcineurin Inhibitors*/Calcineurin Inhibitors*/adverse effects ; Nephrosis, Lipoid*/Nephrosis, Lipoid*/Nephrosis, Lipoid*/diagnosis

  • Source: Nephrology (Carlton, Vic.) [Nephrology (Carlton)] 2016 Oct; Vol. 21 (10), pp. 893-900.Publisher: Blackwell Science Country of Publication: Australia NLM ID: 9615568 Publication Model: Print Cited Medium: Internet ISSN: 1440-1797

Record details

Read Online Read More Add to Saved list
×
  • 1-10 of  214 results for ""RITUXIMAB""